This inventor holds 3 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Glaxosmithkline Intellectual Property Development Limited, Glaxo Group Limited. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2020-2026
Title: Peter Morley: Innovator in Antigen Binding Proteins
Introduction
Peter Morley is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins and modified proteins. With a total of 3 patents to his name, Morley's work has the potential to impact the treatment of various diseases.
Latest Patents
Morley's latest patents include innovative compositions for treating CD96 mediated diseases. The first patent focuses on antigen binding proteins, detailing methods and compositions that can be utilized in therapeutic applications. The second patent involves modified proteins and peptides that exhibit a reduced ability to bind to pre-existing antibodies. These modified molecules can include C-terminal additions, extensions, or specific amino acid substitutions, enhancing their utility in medical formulations.
Career Highlights
Throughout his career, Peter Morley has worked with prominent organizations, including GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited. His experience in these companies has allowed him to refine his expertise in patent development and biotechnology.
Collaborations
Morley has collaborated with notable colleagues such as Yan Y Degenhardt and Jun Guan. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Peter Morley is a distinguished inventor whose work in antigen binding proteins and modified proteins has the potential to revolutionize treatments for various diseases. His contributions to biotechnology and his collaborations with esteemed colleagues highlight his commitment to innovation in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile